Manufacturing News and Research

RSS

Manufacturing is the production of products across all industries, on a large-scale, using machinery.

Star Scientific develops moist snuff tobacco product with low carcinogenic levels

Star Scientific, Inc. reports that it has successfully developed a moist snuff tobacco product that has extremely low levels of carcinogens -- much lower than any snuff products currently in the marketplace. This new product has levels of tobacco-specific nitrosamines (TSNAs) -- recognized by scientists worldwide as one of the most powerful cancer-causing agents in tobacco leaf and smoke -- below 20 parts per billion (nanograms-per-gram moist weight, as used) in initial testing.

4 Jan 2011

Embryome Sciences announces $4M equity financing, changes name to ReCyte Therapeutics

BioTime, Inc. today announced a $4 million equity financing by its subsidiary, Embryome Sciences, Inc. Concurrent with the financing, Embryome Sciences will be renamed ReCyte Therapeutics, Inc. and will develop therapeutic products for cardiovascular and blood diseases. The new equity financing is being led by a $2.5 million investment by private investors and a $1.5 million investment from BioTime that valued ReCyte Therapeutics at a post money valuation of $60 million on a fully diluted basis.

4 Jan 2011

Stryker acquires Boston Scientific's Neurovascular business

Boston Scientific Corporation today announced that it has completed the sale of its Neurovascular business to Stryker Corporation.

From Stryker 3 Jan 2011

FDA clears ACT's IND to treat AMD using hESC derived RPE cells

Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, announced today that the US Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application to treat Dry Age-Related Macular Degeneration (AMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs).

3 Jan 2011

CEL-SCI initiates Multikine Phase III trail for head and neck cancer

CEL-SCI Corporation announced today that it has commenced its Phase III clinical trial for Multikine®, the Company's flagship immunotherapy. CEL-SCI has now completed all of the manufacturing and regulatory requirements to begin enrollment of the study.

29 Dec 2010

Chindex announces joint venture deal with Fosun Pharma

Chindex International, a leading independent American provider of Western healthcare products and services in the People's Republic of China, and Shanghai Fosun Pharmaceutical, a leading manufacturer and distributor of western and Chinese medicine and devices in China, today announced the formation of the previously-proposed joint venture to independently operate certain combined medical device businesses, including Chindex's Medical Products division.

28 Dec 2010

ACT, Roslin Cells collaborate to establish hESC line bank using single-ceblastomere technique

Advanced Cell Technology, a leader in the field of regenerative medicine, announced today that it has entered into a Memorandum of Understanding with Roslin Cells LTD of Scotland, in which the two companies contemplate a definitive collaboration agreement in the near future.

28 Dec 2010

Alimera receives FDA CRL for ILUVIEN NDA

pSivida Corp., a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, including the investigational drug ILUVIEN® for the treatment of Diabetic Macular Edema (DME), today announced that Alimera Sciences, Inc, pSivida's collaborative partner, received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for ILUVIEN. The FDA issued the CRL to communicate its decision that the NDA cannot be approved in its present form.

24 Dec 2010

MiMedx receives notification of Class III certification for HydroFix technology

MiMedx Group, Inc., an integrated developer, manufacturer and marketer of patent protected biomaterial-based products, announced today that it has received notification of the Class III certification for a European product using the Company's proprietary HydroFix technology.

24 Dec 2010

InfraReDx to receive $862,000 as part of MLSC Tax Incentive Program

InfraReDx, Inc., a medical device company developing intelligent cardiovascular diagnostic imaging technologies, today announced that it has been selected to receive an award of nearly $862,000 as part of the Massachusetts Life Sciences Center Tax Incentive Program. In conjunction with the award, InfraReDx has committed to create 32 new jobs during 2011.

24 Dec 2010

Bonovo Orthopedics announces closing of $10M Series C Preferred Stock financing

Bonovo Orthopedics, Inc., a leading provider of orthopedic products to the Chinese healthcare market, announced today that it closed a US$10 million Series C Preferred Stock financing. The financing was led by OrbiMed Asia Partners and was participated in by Legend Capital and Bonovo's existing shareholders.

24 Dec 2010

Medicago completes first part of H5N1 vaccine Phase II trial

Medicago, a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles, today announced that the last dose of vaccine has been administered completing the first part of the Company's Phase II human clinical trial with its H5N1 Avian Influenza vaccine.

23 Dec 2010

FDA joins Abbott Diabetes Careto to recall 359 glucose test strips

The test strips being recalled may give falsely low blood glucose results. False results may lead patients to try to raise their blood glucose unnecessarily, or they may fail to treat elevated blood glucose because of a false, low reading. Both scenarios pose risks to a patient's health.

22 Dec 2010

Amorcyte reports AMR-001 phase I trial results in heart attack patients

The American Heart Journal today reported results of a clinical trial evaluating Amorcyte, lead product candidate, AMR-001 for the treatment of damaged heart muscle following acute myocardial infarction.

22 Dec 2010

Mesa Labs announces acquisition of Apex's biological indicators business

Mesa Laboratories, Inc., a Lakewood, Colorado based manufacturer of electronic instruments and disposables today announced the acquisition of the biological indicators business of Apex Laboratories, Inc., a North Carolina based company. The acquisition of the Apex business is expected to be immediately accretive to Mesa's earnings per share.

22 Dec 2010

Tap water cancer chemical detected

A new analysis has revealed a potential carcinogen in the tap water of 31 U.S. cities and experts are looking for ways to reduce exposure of the communities. The chemical called hexavalent chromium, got public attention in the 2000 film “Erin Brockovich” and has been found to cause cancer in laboratory animals by the National Toxicology Program, part of the National Institutes of Health.

21 Dec 2010

Biovest issues FAQ update on BiovaxID personalized cancer vaccine

Biovest International, Inc. today issued the following update in the form of a "Frequently Asked Questions" report in response to the high volume of inquiries received following the Company's recent presentation at the 2010 American Society of Hematology Annual Meeting (ASH 2010) in Orlando, Florida.

21 Dec 2010

BioInvent, Japanese pharmaceutical extends partnership for therapeutic candidate development

BioInvent International AB today announced that it has signed an agreement to extend its existing collaboration with an undisclosed Japanese pharmaceutical group.

21 Dec 2010

Amylin submits metreleptin rolling submission BLA for treatment of rare forms of lipodystrophy

Amylin Pharmaceuticals, Inc. today announced that it has submitted the initial sections of a rolling submission for a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the use of metreleptin to treat diabetes and/or hypertriglyceridemia (high levels of triglycerides in the bloodstream) in patients with rare forms of lipodystrophy.

21 Dec 2010

Royal DSM to acquire Martek for $1,087 million

Royal DSM N.V., the global Life Sciences and Materials Sciences company, and Martek Biosciences Corporation today announce that they have entered into a definitive agreement under which DSM will acquire all the outstanding shares of common stock of Martek for US$31.50 in cash per share for total consideration of US$1,087 million.

21 Dec 2010

Manufacturing News and Research

Further Reading

Star Scientific develops moist snuff tobacco product with low carcinogenic levels

Embryome Sciences announces $4M equity financing, changes name to ReCyte Therapeutics

Stryker acquires Boston Scientific's Neurovascular business

FDA clears ACT's IND to treat AMD using hESC derived RPE cells

CEL-SCI initiates Multikine Phase III trail for head and neck cancer

Chindex announces joint venture deal with Fosun Pharma

ACT, Roslin Cells collaborate to establish hESC line bank using single-ceblastomere technique

Alimera receives FDA CRL for ILUVIEN NDA

MiMedx receives notification of Class III certification for HydroFix technology

InfraReDx to receive $862,000 as part of MLSC Tax Incentive Program

Bonovo Orthopedics announces closing of $10M Series C Preferred Stock financing

Medicago completes first part of H5N1 vaccine Phase II trial

FDA joins Abbott Diabetes Careto to recall 359 glucose test strips

Amorcyte reports AMR-001 phase I trial results in heart attack patients

Mesa Labs announces acquisition of Apex's biological indicators business

Tap water cancer chemical detected

Biovest issues FAQ update on BiovaxID personalized cancer vaccine

BioInvent, Japanese pharmaceutical extends partnership for therapeutic candidate development

Amylin submits metreleptin rolling submission BLA for treatment of rare forms of lipodystrophy

Royal DSM to acquire Martek for $1,087 million

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest Life Science News